Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

e to research and development. This compares to operating expenses of $19.6 million and research and development expenses of $17.6 million for the same nine month period last year. The Company reported a net loss for the nine months ended September 30, 2007 of $15.2 million compared to a net loss of $12.2 million for the same period last year.

TorreyPines merged with Axonyx Inc. on October 3, 2006. The Company's financial statements reflect the historical results of TorreyPines prior to the merger and that of the combined company following the merger, and do not include the historical results of Axonyx Inc. prior to the completion of the merger.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel as a treatment for migraine, the potential timing, development and initiation of Phase III clinical trials of tezampanel, the potential for NGX267 to treat the symptoms of cognitive impairment associated with schizophrenia and the potential for NGX267 to treat dry mouth, or xerostomia. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPin
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  The full interim results will be presented ... and IGF Society, being held October 15-18, 2014, ...
(Date:9/16/2014)... September 16, 2014 BCC Research ... FOR STEM CELLS , the global market for stem ... by 2018, with a five-year compound annual growth rate ... in the Americas with growth projections of $2.2 billion ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Anesiva,Inc. (Nasdaq: ANSV ) announced today the ... directors. Mr. Janney previously served on Anesiva,s,board from November ... following the merger of Anesiva and AlgoRx Pharmaceuticals., ... of directors,and we are very pleased to welcome him ...
... Inc.,today announced that Edward L. Jacobs, president and ... medical officer,will present an update of the company,s ... Feb. 13, 2008, at the BIO CEO & ... will include information about Semafore,s lead product,candidate, SF1126, ...
... Diagnostic Imaging,International Corp. (OTCBB: DIIG) announced today that ... imaging clinics for acquisition., Following the Company,s ... of profitable operating clinics as well as open ... begun its diligence review on clinics that have,been ...
Cached Biology Technology:Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3Semafore to Present at BIO CEO & Investor Conference 2Diagnostic Imaging - Acquisitions - OTCBB: DIIG 2
(Date:9/16/2014)... Fla. , Sept. 16, 2014  Cross ... identity management solutions, announced today the launch of ... to authenticate the identity of an individual using ... Android-based Verifier Sentry rapidly reads credential documents with ... ID by matching the biometric to a live ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... research has determined that a single group of microorganisms ... B12 production in the oceans, with implications for the ... B12 is an essential molecule required by most life ... relatively small group of microorganisms because it is so ... key role in maintaining the brain and nervous systems, ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... Johnson & Johnson today announced that Axel Ullrich, Ph.D., ... Max Planck Institute of Biochemistry in Germany, whose discoveries ... , is the winner of the 2009 Dr. Paul ... of world-renowned scientists selected Dr. Ullrich, who on September ...
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... time, scientists have shown that chromosomal abnormalities are present ... produced by young, fertile couples. Ms Evelyne Vanneste, a ... the University Fertility Center, Leuven University, Belgium, told the ... Reproduction and Embryology today (Wednesday July 1), that the ...
Cached Biology News:Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Genetically engineered mice yield clues to 'knocking out' cancer 2Chromosomal problems affect nearly all human embryos 2Chromosomal problems affect nearly all human embryos 3
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
... Physical form: Essentially sulfate-free, powder ... Preparation Unit Definition: One ... D -fructose 6-phosphate to ... pH 7.4 at 25 C. ...
Biology Products: